There are 2949 resources available
1805P - Apatinib combined with irinotecan in the treatment of small cell lung cancer: A phase II, single-arm, prospective study
Presenter: Yanbin Zhao
Session: E-Poster Display
Resources:
Abstract
1806P - Final safety and efficacy data from CLEPSIDRA trial in 2L ED-SCLC
Presenter: Alejandro Navarro Mendivil
Session: E-Poster Display
Resources:
Abstract
1807P - Real world data on 442 patients (p) with small cell lung cancer (SCLC) treated in the last ten years at Vall d’Hebron Hospital
Presenter: Nadia Saoudi Gonzalez
Session: E-Poster Display
Resources:
Abstract
1808TiP - Atezolizumab (ATZ) in combination with carboplatin (Cb) and etoposide (Eto) in the treatment of patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC): A multicenter, phase IIIb, single arm, safety study (MAURIS trial)
Presenter: Giulia Martini
Session: E-Poster Display
Resources:
Abstract
1819P - Determinants of new onset cardiovascular disease (CVD) in cancer patients
Presenter: Atul Batra
Session: E-Poster Display
Resources:
Abstract
1820P - Taxane-related skin toxicity: Analysis of an in vivo and 3D in vitro model study of the impact of paclitaxel on skin
Presenter: Martin Perez-Leal
Session: E-Poster Display
Resources:
Abstract
1821P - A multicentre analysis of toxicity in 6 weekly vs 3 weekly pembrolizumab dosing
Presenter: Michael Rowe
Session: E-Poster Display
Resources:
Abstract
1822P - Impact of iron-deficiency management on quality of life in cancer patients: A prospective cohort study (CAMARA study)
Presenter: Cassandre Gluszak
Session: E-Poster Display
Resources:
Abstract
1823P - Characterization of thrombosis risk in patients with cancer: Preliminary results
Presenter: Pablo Cerezuela
Session: E-Poster Display
Resources:
Abstract
1824P - Incidence, risk factors and clinical outcome of venous and arterial thromboembolism in patients treated with immune-checkpoint inhibitors
Presenter: Florian Moik
Session: E-Poster Display
Resources:
Abstract